诚信认证:
工商注册信息已核实!
伯舒替尼 (SKI-606),380843-75-4,≥99%
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
阿拉丁 | 总代理 | 中国 | 现货 |
性能特点
Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effective
货号 | 规格 | CAS号 | 价格 | 操作 |
---|---|---|---|---|
B129905-10mg | 10mg | 380843-75-4 | ¥221.90 | 询底价 |
B129905-50mg | 50mg | 380843-75-4 | ¥488.90 | 询底价 |
B129905-100mg | 100mg | 380843-75-4 | ¥631.90 | 询底价 |
B129905-1g | 1g | 380843-75-4 | ¥4,556.90 | 询底价 |
B129905-250mg | 250mg | 380843-75-4 | ¥1,340.90 | 询底价 |
中文名:伯舒替尼 (SKI-606)
英文名:Bosutinib (SKI-606)
中文别名:伯舒替尼
英文别名:SKI-606|WAY-173606|Bosutinib,SKI-606|BSPBio_001023|NCGC00241107-03|NSC799367|NSC-799367|4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile|5018V4AEZ0|DB06616|SK 606|2-[4-(2,3-dihydro-1,4-benzodi
纯度:≥99%
货号:B129905
Cas号:380843-75-4
产品介绍:
Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration.A c-Abl, Src-Abl, and Bcr-Abl inhibitor
查看阿拉丁官网此产品相关对应页面:https://www.aladdin-e.com/zh_cn/B129905.html
伯舒替尼 (SKI-606),380843-75-4,≥99%信息由上海阿拉丁生化科技股份有限公司为您提供,如您想了解更多关于伯舒替尼 (SKI-606),380843-75-4,≥99%报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途